Literature DB >> 10714359

Vasopressin receptor mutations and nephrogenic diabetes insipidus.

M Birnbaumer1.   

Abstract

X-linked recessive nephrogenic diabetes insipidus is caused by mutations in the gene encoding the V2 vasopressin receptor (V2R), the mediator of the antidiuretic effect of arginine vasopressin (AVP) in mammalian kidneys. Upon binding to AVP, the receptor activates the G protein Gs, stimulating a phosphorylation cascade that promotes translocation of presynthesized water channels to the apical surface of the principal cells lining the last segments of the nephron. The presence of these channels allows the flow of water from the hypotonic lumen of the nephron into the hypertonic interstitium. More than 100 different mutations have been identified since the receptor gene was characterized--in most cases one per family, although some families bear two and three mutations in the same gene. The frequency of the de novo mutations identified suggests that the DNA at the end of the long arm of the X chromosome is very susceptible to alteration. The mutations are scattered within the coding region, not confined to a particular segment of the receptor protein, and in most cases confined to a single amino acid change that significantly reduces the number of receptors present on the plasma membrane. Some mutations do not affect protein synthesis but significantly reduce the coupling efficiency between the receptor and G protein. Analysis of the biochemical impact of the mutations has provided valuable information about the synthesis and regulation of the receptor.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10714359     DOI: 10.1016/s0188-4409(99)00063-6

Source DB:  PubMed          Journal:  Arch Med Res        ISSN: 0188-4409            Impact factor:   2.235


  8 in total

1.  The effect of aspartate-lysine-isoleucine and aspartate-arginine-tyrosine mutations on the expression and activity of vasopressin V2 receptor gene.

Authors:  Hossein Najafzadeh; Leila Safaeian; Hamid Mirmohammad Sadeghi; Mohammad Rabbani; Abbas Jafarian
Journal:  Iran Biomed J       Date:  2010 Jan-Apr

2.  Heterologous downregulation of vasopressin type 2 receptor is induced by transferrin.

Authors:  Richard Bouley; Paula Nunes; Billy Andriopoulos; Margaret McLaughlin; Matthew J Webber; Herbert Y Lin; Jodie L Babitt; Thomas J Gardella; Dennis A Ausiello; Dennis Brown
Journal:  Am J Physiol Renal Physiol       Date:  2012-12-12

3.  Regulation of the vasopressin V2 receptor by vasopressin in polarized renal collecting duct cells.

Authors:  J H Robben; N V A M Knoers; P M T Deen
Journal:  Mol Biol Cell       Date:  2004-10-06       Impact factor: 4.138

4.  Mutation of the histidin residue of the DRH motif in vasopressin V2 receptor expression and function.

Authors:  H Mir Mohammad Sadeghi; M Rabbani; A Jafarian; H Najafzadeh; L Safaeian
Journal:  Daru       Date:  2010       Impact factor: 3.117

5.  New insights into the transcriptional regulation of aquaporin-2 and the treatment of X-linked hereditary nephrogenic diabetes insipidus.

Authors:  Hyun Jun Jung; Tae-Hwan Kwon
Journal:  Kidney Res Clin Pract       Date:  2019-06-30

Review 6.  Targeting trafficking as a therapeutic avenue for misfolded GPCRs leading to endocrine diseases.

Authors:  Alfredo Ulloa-Aguirre; Teresa Zariñán; Rubén Gutiérrez-Sagal; Ya-Xiong Tao
Journal:  Front Endocrinol (Lausanne)       Date:  2022-08-25       Impact factor: 6.055

7.  How genetic errors in GPCRs affect their function: Possible therapeutic strategies.

Authors:  Henriette Stoy; Vsevolod V Gurevich
Journal:  Genes Dis       Date:  2015-06

8.  Pharmacoperone rescue of vasopressin 2 receptor mutants reveals unexpected constitutive activity and coupling bias.

Authors:  Jo Ann Janovick; Timothy P Spicer; Thomas D Bannister; Louis Scampavia; P Michael Conn
Journal:  PLoS One       Date:  2017-08-02       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.